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Y 1980, when this story begins, much was already known about the immune system and its molecules, although wide gaps remained in our knowledge. The major components, B and T lymphocytes, were more or less understood, the former as producers of immunoglobulin antibodies and the latter as agents of cellular immune response. Very laborious protein studies had succeeded in determining the amino acid sequence of a few immunoglobulin molecules. A major puzzle, the existence of an apparently unlimited repertoire of antibody specificities that seemed incompatible with the limited coding capacity of our genome, had just been solved (Gearhart 2004) . The seminal article of Hozumi and Tonegawa (1976) had shown, using techniques that now seem incredibly cumbersome, that the V and the C immunoglobulin gene segments are separated in germline DNA and are joined in differentiated DNA. This was the very first gene rearrangement demonstrated in mammalian DNA, and it led to intense activity over the succeeding years that included cloning the numerous sequences involved in the assembly of a functional immunoglobulin gene and beginning to unravel the mechanisms and the molecules implicated in the execution and the regulation of these rearrangements (Honjo et al. 1981) .
T lymphocytes were also considered essential elements, but their complexity was only partially understood. They were known to include several classes, notably cytotoxic T cells directed against foreign cells (as in graft rejection) or against virus-infected autologous cells, and ''helper'' T cells involved-in some stillmysterious fashion-in stimulating the production of specific antibodies. Several types of cell-surface molecules had been identified, among which were the class I histocompatibility antigens expressed on most cell types and recognized by cytotoxic T lymphocytes: HLA-A, -B, and -C in humans and H-2 K, D, and L in mice. These had originally been identified in the (artificial) context of graft rejection (hence their name), and their characterization at the serological and functional level motivated the Nobel prize awarded in 1980 to Baruj Benacerraf, Jean Dausset, and George Snell. HLA (or H-2) class II antigens, expressed mostly on B cells and involved in recognition by helper T cells, had also been defined. And the T-cell receptor, expressed on T cells and responsible for these recognition events, would eventually be discovered-although this was still in the future.
The HLA (or the mouse H-2) genes and molecules raised many interesting questions that made them a prime target for molecular study, as detailed in Jean Dausset's Nobel Prize lecture (Dausset 1981) . The class I antigens, in particular, displayed a surprising level of polymorphism, first detected by serological analyses but later documented by protein sequencing (Orr et al. 1979) . In spite of their inherent difficulty (they required the purification of a transmembrane protein present in low amounts at the cell surface), these studies had 1 Author e-mail: jordan@genopole.univ-mrs.fr shown that the class I molecule consisted of three extracellular domains followed by a transmembrane segment and a short cytoplasmic tail and that it was associated at the cell surface with a smaller, nonpolymorphic protein called b-2 microglobulin. Interestingly, the first (outer) two extracellular domains, a-1 and -2, displayed extensive polymorphism while the third, a-3, appeared to be constant. Thus the situation seemed formally analogous to that of the immunoglobulin genes, with their variable V and constant C domains, and there was much speculation that some kind of recombination or alternative splicing mechanism was operating to generate the extensive diversity at the HLA class I locus (Bodmer 1981) -at that time, by far the most polymorphic region known in the human genome. It was widely hoped that the isolation of the corresponding genes would throw light on these issues while also providing a wealth of individual HLA sequences, and this goal was accordingly pursued by top laboratories across the world.
THE PATH TO CLONING HISTOCOMPATIBILITY GENES
In 1980, recombinant DNA technology was still very cumbersome, saddled with extremely restrictive legislation, and performed in only a few laboratories; the first isolation of human genes had occurred only two years previously (Lawn et al. 1978) . For the immunoglobulin genes, the task had been somewhat facilitated by the existence of hybridomas (in the mouse) or myelomas (in humans), situations in which abnormal proliferation of a single species of B cells made it possible to purify a given immunoglobulin molecule or, for cloning purposes, to have access to messenger RNA in which the specific messenger was present in relatively large amounts (several percent). None of this was available for histocompatibility genes, so the task appeared quite formidable given the low abundance of the corresponding proteins on the cell surface. In the 1980s, there was of course no human genome sequence, very few genomic or cDNA libraries existed, PCR had not yet been invented, and the road to gene isolation went necessarily through cDNA cloning from messenger RNA followed by probing of genomic libraries.
One of the major laboratories involved in this field, that of Jack Strominger at Harvard, succeeded in isolating a cDNA clone coding for part of an HLA class I protein early in 1980 (published in October of that year: Ploegh et al. 1980 ). This represented a major effort using what was then cutting-edge technology and drawing heavily on resources accumulated by this excellent laboratory. The first step had been electrophoretic fractionation of total cellular mRNA from HLA-expressing cell lines and assessment of each mRNA fraction (after elution from gel slices) by in vitro translation and immunoprecipitation of the products with an HLA-specific antibody 1 to detect the HLA mRNA-containing fractions. The partially purified HLA mRNA thus obtained was then copied into cDNA and cloned in a plasmid vector. Screening of this library was accomplished by a very laborious procedure: DNA preparations from hundreds of individual cDNA clones were individually immobilized on nitrocellulose filters, which were then hybridized with cellular mRNA. After washing, the mRNA that had remained bound to each filter was eluted and tested again in an in vitro translation reaction followed by immunoprecipitation of the translation products with the anti-HLA antibody. Eventually, one cDNA clone that selectively bound mRNA that directed the synthesis of HLA-like material in vitro was found. Its DNA sequence, when determined and translated into protein, gave a peptide sequence identical to that of the HLA B7 protein in its transmembrane region (the HLA B7 protein sequence had been obtained previously in the same group). Thus the clone, called pHLA-1, represented a bona fide HLA probe. This result had been achieved by a very cumbersome procedure, typical of the techniques necessary at that time to achieve cDNA cloning, which required a major effort by excellent scientists and access to highly specific reagents. The success of the Strominger group was to be followed by the isolation of a murine H-2 cDNA clone by the groups of Philippe Kourilsky (Institut Pasteur) and Bernhard Dobberstein (European Molecular Biology Laboratory), using a generally similar approach (published in January 1981 in Kvist et al. 1981) , and also by the identification of another HLA cDNA by Sherman Weissman's group (Yale University), using oligonucleotide probes ''reverse derived'' from the known HLA-B7 protein sequence, a very innovative approach at the time (published in March 1981 in Sood et al. 1981) .
These cDNAs were quickly used to achieve a glimpse at the genomic organization of HLA (or H-2) class I genes, using the then-new technique of Southern blots. A surprising finding soon emerged: the number of bands seen on a Southern blot was much larger than expected: 20-40 bands (i.e., approximately as many genes), whereas only three genetic loci (HLA-A, -B, and -C or H-2 K, D, and L) were known. Were these cryptic genes somehow related to the extensive polymorphism of the HLA locus? Did they correspond to hidden alleles waiting to be expressed? As it turned out later, many of these additional genes were in fact pseudogenes, or nonfunctional sequences. But this finding had to await the actual isolation and sequencing of genomic clones, a feat that was not obvious at that time even given the availability of bona fide cDNA clones. There was no central resource offering a variety of goodquality genomic libraries. Cosmid cloning was just 1 This had to be a very special reagent to detect in vitro-translated HLA chains not associated with b2 microglobulin. Availability of this serum in the Strominger lab was one of the key elements of success.
beginning, YACs and BACs were of course unknown, and libraries of genomic DNA cloned into l-phage vectors were still state of the art, in spite of their shortcomings (insert size limited to 10-15 kb, cumbersome screening procedures and tendency to instability). In addition, it was widely believed that cross-species screening (using a mouse probe on human DNA or vice versa) would be quite difficult. As it turned out, however, the first mouse H-2 gene was isolated using a human HLA probe, and the first HLA gene was isolated using a mouse H-2 probe. It is the latter story that I now will recount.
THE ROAD TO THE FIRST HLA GENE Early in 1980 and as the HLA/H-2 race went on, I was in the process of moving to the Centre d'Immunologie Marseille-Luminy (CIML), an innovative research structure established in 1976 in a (then) sparsely populated campus on the Southern outskirts of Marseille. I had been attracted there by the high quality of research, by the dynamic structure of the organization (nonpermanent groups, rotating directorship), and by the strongly expressed policy of developing DNA-based approaches applied to immunological questions. Indeed, this excellent institute, largely populated by research groups that had migrated together from Paris, was limited, in terms of techniques, to mouse physiology, serology, and cellular immunology, with one laboratory active in protein sequencing. My group, established at CIML in Spring 1980, was the first to introduce DNA-based approaches, and it was really a treat to do so in an environment where these were obviously needed and where this need was realized by the existing groups that immediately proposed a number of collaborations. Nevertheless, finding an immunological question quite ripe for a molecular approach was not so obvious, and so my small group (four people including myself) started working on a relatively low-key issue, the cloning of rat immunoglobulin D (IgD). This particular immunoglobulin subtype had not yet been studied at the DNA level, and the rat had been chosen because of the existence of a hybridoma overexpressing that particular protein that provided a source of enriched mRNA. Progress was relatively slow because my previous experience with recombinant DNA had not included mRNA purification or cDNA cloning. I had been investigating the genomic organization and sequence of Drosophila ribosomal genes, using the ribosomal RNA species as probes, and was reasonably familiar with restriction mapping, Southern blotting, subcloning, and sequencing but not with cDNA synthesis and isolation. Of course, my new collaborators from CIML were even less experienced than myself in these technologies.
However, Franc xois Kourilsky, the initial director of CIML, 2 understandably had a direct line to events taking place at his brother's (Philippe Kourilsky) laboratory at the Institut Pasteur. By the summer of 1980, Franc xois Bregegere in Philippe's group had indeed obtained the H-2 class I cDNA clones that would be published in May 1981, and the rash idea of using them to identify HLA genes soon emerged-a rash idea because at that time the strong similarity between mammalian coding sequences was not common knowledge, and such an approach seemed very adventurous and with little chance of success. But why not try? After discussing step-by-step approaches such as probing human Southern blots or human cDNA libraries with the mouse probes under relaxed hybridization conditions (to allow for sequence divergence), we finally decided to go directly for human genomic HLA clones by screening a human library. Arrangements were made, and, in late October 1980, I found myself in Paris in the very cramped surroundings of Philippe Kourilsky's lab (then occupying poorly adapted space in the old buildings of the Institut Pasteur), learning to handle l-phage libraries, pick plaques, and go through library screening procedures with radioactive probes. In fact, a limited primary screening of the so-called ''Maniatis library'' (constructed in the l-phage Charon 4A with $15-kb inserts; see Lawn et al. 1978) had already been carried out by Brigitte Cami, Philippe's excellent senior technician. In half a human genome's equivalent (100,000 clones), dozens of positive plaques had appearedalmost too many! Primary screening, which was performed on phage plated on bacterial lawns at very high density, gave weak signals, and the phage picked out from the plates were still a complex mix, so I had to go through two rounds of secondary screening and purification of these positives. In a couple of weeks, I ended up with 15 phage clones that gave strong signals on hybridization with the mouse probe-even at high stringency, which seemed somewhat strange-and that, according to limited analyses with restriction enzymes, appeared to be different. I made medium-scale DNA preparations from all these phages, and, on November 21, left for Marseille with a box of small vials-and a great hope in my heart! While in Paris, I had been able to obtain up-to-date indications on positions in the cloning race through discussions with colleagues. Jack Stominger's group had just published their HLA cDNA, and they were said to be busy sequencing a genomic clone. Sherman Weissman's laboratory had already obtained an HLA cDNA clone (to be published in January 1981), and this had reportedly been provided to Lee Hood's group in Pasadena, California, for an attempt at H-2 genomic cloning. But no one seemed to have definite identification of a cloned gene, so there was still a window of opportunity, provided that I was able to conclusively identify and sequence an HLA genomic clone among my vials, although I was competing with large, well-known, and well-established molecular genetics groups. In fact, my return to Marseille was less than idyllic. The three members of my still embryonic group, laboring on IgD cDNA cloning, felt left out of the HLA project that generated great enthusiasm from other group leaders at CIML and that was quite obviously my major interest. And my precious phages misbehaved: when I made new DNA preparations, results were in many cases different from what I had seen in Paris. Obviously, some kind of instability was at work and was playing havoc with the restriction maps and the hybridization patterns. I decided to concentrate on one phage that seemed reasonably well behaved, called l12, and to forget the grumblings of my lab associates and get on with the work.
An essential step was to obtain sequence information confirming (hopefully!) that the clone did indeed contain sequences coding for an HLA protein. This step was made more difficult by the fact that the Maniatis human genomic library had been constructed with DNA from a human placenta of unknown HLA type. I had been introduced to basic recombinant DNA techniques during a sabbatical at Imperial College (London) in [1978] [1979] in the laboratory of David Glover and Peter Rigby, who were then just back from their postdoc in the United States. I had also learned DNA sequencing at the Laboratory of Molecular Biology, Cambridge (UK), with a close associate of Fred Sanger, George Brownlee, who, strangely enough, was not using Sanger sequencing (Sanger et al. 1977) but instead the competing method developed by Maxam and Gilbert (1977) , which relied on chemical cleavage of the DNA rather than on synthesis in the presence of terminators.
3 This may actually have been an advantage since the Maxam-Gilbert technique, although cumbersome and saddled with noxious chemicals such as hydrazine or dimethylsulfate, allowed direct sequencing at the ends of a fragment of any size, as long as it was radioactively labeled, without extensive subcloning. The choice of the fragment to be sequenced was of course critical, since only exon sequences could be recognized by comparison with the two existing HLA protein sequences, whereas introns were expected to occupy the majority of the space. Actually, two mouse cDNA fragments were available as probes from the Pasteur group, one of which was only 195 bases long and, according to its sequence, coded for part of the third domain of the H-2 protein. Fortunately, limited restriction enzyme analysis of l-12 had shown that, after cleavage with the SstI enzyme, two different fragments hybridized with the H2-2 probe. Therefore, the cleavage site for this enzyme could be expected to lie within the region complementary to the probe, i.e., within the stretch coding for the conserved third domain.
I accordingly prepared some l-12 DNA, cleaved it with SstI, incubated the mix of fragments obtained with alkaline phosphatase and 32 P-labeled triphosphates (thus labeling the two 59 ends of the fragments on either DNA strand), and then recut with the Bgl II enzyme, which I knew would cleave one of the two SstI fragments that hybridized with the H2-2 probe and therefore result in a segment with only one end-label, i.e., that could be directly sequenced using MaxamGilbert chemistry. By then, we were well into December, with no further news from the United States, fortunately: the race still appeared to be on. My lDNA preparations had not worked very well, and the labeling systems were relatively inefficient; moreover, the isolation of the fragment to be sequenced involved its elution from an agarose gel, a low-yield procedure. Thus I ended up with a small amount of labeled DNA ( just 100,000 radioactive counts of material), just enough for one set of reactions and a couple of sequencing gels if everything went well. After performing the rather tedious series of mixes and incubations involved in the Maxam-Gilbert procedure, I finally loaded an 8% acrylamide gel on the morning of December 20, ran it for most of the day, and exposed it to X-ray film in the late afternoon. At that time, imaging plate systems were unheard of in biology labs (they became popular almost 10 years later), and the only way to reveal radioactive bands displayed by a sequencing gel was to use large medical X-ray films, carefully removing the thin acrylamide gel from its glass plates and placing it with the film in a light-tight cassette for exposure at À80°and later development-all in the darkroom, of course. Since I had loaded only part of my reactions on the gel (reserving the rest for repeats or different electrophoresis conditions), I was expecting rather faint signals and accordingly decided on exposure over the weekend (December 20 being a Saturday).
Thus, first thing early on the following Monday, I locked myself in the darkroom to develop the film for this initial sequencing experiment. Needless to say, my adrenalin level was quite high. Would the exposure be sufficient? Would I see something? Would the bands be sharp and readable, or fuzzy and blurred, as sometimes happened for a number of reasons? As soon as the large film was in the fixing solution, I pulled it out to have a look under the faint red illumination of the room: things looked okay, with nice dark bands and a clear background. I forced myself to leave the gel in the fixer for the required 5 min, then washed it briefly, and turned on the light. Yes, the experiment had worked well, and I could expect to extract 50-100 nucleotides of sequence from that particular gel and exposure. Now the question was whether or not this sequence was going to tell me anything. So I quickly read the 30 or 40 clearest nucleotides from the still-wet gel, and set out, pencil in hand, to see if this sequence made any sense. At the time, there were no gel readers, no personal computers, and no Word files: all lab notes were taken by hand, and sequence interpretation was a human 3 This may have been an instance of Oedipal ''father-killing'' syndrome.
game. From the nature of the H-2 probe used, I knew that, if I had hit an exon, this was likely to code for sequences in the most conserved part of the molecule, the third extracellular domain, for which two protein structures were available, corresponding to HLA-B7 and to HLA-A3 specificities. Naturally ''my'' gene (if indeed it was there) had no reason to be either B7 or A2, but it should be sufficiently similar to be recognizable-or at least I hoped so. In addition, not knowing the orientation of the l-insert or of the reading phase, there were in fact six ways to interpret this short DNA sequence. So I started writing down the possible translations, eliminated those that contained a stop codon, and compared the remaining ones to the HLA-B7 protein. My heartbeat accelerated when one of them began to look very similar, and it almost stopped when it turned out to be identical to a series of nine amino acids in the HLA-B7 third domain (Figure 1 ). There I was, at 10 min past 9 a.m. on December 22, 1980, and the very first gel run on the very first sequencing experiment of my first putative HLA clone had just told me that this indeed contained at least part of an HLA gene.
FOLLOWING UP
These initial results were important enough in the context of the time to justify a short letter to the editor of Nature, sent in January and published in April 1981, which essentially presented the results described above and the l-clone, now rechristened l-HLA-12 ( Jordan et al. 1981) . From then on, the path was clear: the whole clone had to be sequenced as quickly as possible, hoping that it contained a complete HLA gene. As it turned out, I did not have to go through the whole l-insert because a 5.6-kb HindIII fragment subcloned into the plasmid pBR 328 and called pHLA12.4 provided all the necessary information. Sequencing a few thousand bases of DNA was still quite a major undertaking in 1980, involving many sequencing reactions and many more sequencing gels that each revealed up to 100 or 150 nucleotides, followed by the assembly of all these pieces into a global sequence. Fortunately, I was greatly helped in this task by two new associates, Marie Malissen, who had just joined the group as a postdoc with previous experience in a quite different field (marine biology) but who had great energy and a quick learning curve, and Bernard Malissen (her husband), then a member of Claude Mawas's cellular immunology laboratory at CIML, who devoted highly efficient part-time work to the project while also providing his deep knowledge of the immune system and his extensive connections in the corresponding community. 4 Much of the actual sequencing, however, was done with my own hands throughout a highly active 1981 Spring season, during which we obtained and assembled most of the sequence of the plasmid insert. In that Spring, important articles came out, notably the one from Sherman Weissman's group on their high-tech isolation of an HLA cDNA (Sood et al. 1981) and also that of the KourilskyDobberstein group on the H-2 clone that I had used as a probe (Kvist et al. 1981) . Much to our relief, there was no indication of a competing genomic HLA clone. On the other hand, strong rumors indicated that Michael Steinmetz, in Lee Hood's group, had been successful in pulling out an H-2 class I genomic clone using Weissman's HLA cDNA ( just the reverse from us) and was busy sequencing it.
For our sequencing, we stuck to the Maxam-Gilbert method, which was working quite well in my hands, and (Bottom) Enlargement of the notebook page on which the initial data was entered, showing the sequence complementary to the one seen on the gel (left to right on the notebook, top to bottom on the gel) with, above, one of the possible translations into amino acids (one-letter code) and, above again, the corresponding HLA-B7 sequence, which was identical over nine amino acids (the HLA-B7 amino acid at the second position from the left is actually T, not D).
offered some advantages in terms of sequencing strategy. By summer, we were almost sure that pHLA12.4 contained a complete HLA gene: we had found sequences that translated into peptides highly homologous to the known HLA first domain sequences, indicating that the clone was probably complete at the 59 end of the gene, as well as stretches that could be interpreted as transmembrane and cytoplasmic-like. A clear exonintron organization emerged, with each of the three extracellular domains being coded by a separate exon, and a more complex structure in the still fuzzy transmembrane COOH-terminal region. At the time, there continued to be much puzzling over the significance of split genes, but finding that the exon structure mirrored the protein organization (at least in the extracellular portion of the HLA molecule) made great sense. There remained quite a few dubious spots to clear up, however, before arriving at a publishable sequence. Meanwhile, Michael Steinmetz, as expected and feared by us, had made excellent progress with an H-2 class I gene and had already publicized its exon-intron organization, which was very similar to ours. In fact, he had completed the sequence, as I found out during a Keystone meeting that Spring where I presented, to many people's surprise, extensive (but still incomplete) data on our HLA gene sequence. Michael's paper was soon in press and it became clear that this would be the first published class I histocompatibility gene sequence (it came out in the September issue of Cell as Steinmetz et al. 1981) . However, obtaining the first HLA sequence was still a worthwhile goal in spite of the emerging close similarity between the murine and human structures. After taking a 3-week holiday in Greece (to the dismay of Franc xois Kourilsky, who had by then rotated back to being the director of the CIML), I finished the sequence in a few busy weeks during the summer. Another small illumination came when our continuing difficulties with the 39 end of the gene were found to be due to the fact that we had been inverting one large fragment in our gene assembly. Once this fragment was put in the right orientation, everything fit perfectly, and our gene turned out to indeed be complete, with seven exons closely paralleling the protein structure (Figure 2 , bottom). One disappointment emerged: this gene was actually a pseudogene because a critical cysteine known to be necessary for the structure of the second domain was replaced by a phenylalanine. But Steinmetz's gene was also a pseudogene, and it later turned out that these pseudogenes were indeed quite numerous in the class I chromosomal region. By October, we had written an article for the Proceedings of the National Academy of Science of the United States of America, which was communicated by Baruch Benacerraf (president of our scientific council), received excellent reviews (''a major contribution to the fields of human genetics and immunogenetics,'' according to one of the reviewers), and duly came out in the February 1982 issue (Malissen et al. 1982b) .
Many developments followed, too numerous and complex to be described in the framework of this Perspectives article. Major events at CIML were the isolation of cosmid (45-kb insert) clones using a library provided by Richard Flavell's laboratory, which provided a glimpse at the genomic organization of HLA genes 5 and a source of full-length sequences (Malissen et al. 1982a) . We were also able to use mammalian cell transformation to express and characterize functional HLA genes, thanks to the foresight of Pierre Golstein (CIML) who had already been establishing in his group these transformation systems developed in the late 1970s and then very much state of the art (Wigler et al. 1979) . Another active group at CIML, that of Franc xois Lemonnier, had excellent expertise in HLA serology and was able to assess the transformants in detail and to deal with the complexities induced by the fact that the human protein was expressed on mouse, not human, cells and thus associated with murine b-2 microglobulin (Lemonnier et al. 1982 ). Thus we succeeded in publishing the first gene sequences from functional and serologically characterized alleles, HLA-A3 and -CW3, in 1984 (Lemonnier et al. 1983; Sodoyer et al. 1984; Strachan et al. 1984) . Of course, competing laboratories did not remain inactive, and those that had a strong background in functional HLA studies caught up with us, notably with studies on the recognition of HLA molecules by cytotoxic and helper T cells. HLA and H-2 class II genes were isolated in the succeeding years, followed by the T-cell receptor, which proved much more elusive but finally yielded to astute differential cloning approaches. With the identification of many additional receptors, coreceptors, factors, and cytokines, the understanding of recognition events in immunological reactions made quick and major progress.
Today, the HLA class I family comprises at least 26 loci, including 6 nonclassical expressed genes and 17 pseudogenes in addition to the classical HLA-A, -B, and -C loci (Horton et al. 2004) . Our original clone corresponds to the HLA-H pseudogene 6 and lies just telomeric to the HLA-A sequence (Figure 2 ). Much activity continues on this gene-dense, complex, and highly polymorphic region, with particular interest in an expressed gene called HLA-G, just telomeric to HLA-H, whose product is involved in the maternal immunological accommodation of the fetus (Apps et al. 2008) ; in the HFE hematochromatosis locus, which is in fact an HLA-like gene (Feder et al. 1996) ; and in the mechanism by which a particular HLA-B allele, HLA-B27, mediates a very high risk of ankylosing spondilytis (Hü lsmeyer et al. 2004 ). There are still many mysteries in the HLA gene region.
REFLECTIONS ON A ''DISCOVERY''
As the quotation marks in the title above suggest, was this really a discovery? The isolation of a gene does not require deep insight into the mechanisms of life, and the DNA sequence is found, not invented or deduced by sophisticated reasoning. In addition, a feat like this is today completely trivial. At the time, however, ''cloning a gene'' was the major game in molecular biology and difficult enough to necessitate hard work, excellent skills, and inventive strategies. As I have emphasized in my story, the really demanding part was the initial cDNA cloning (not done by us!), and some of the methods used really required great expertise and a high level of resistance to tedium. The cross-species probing that we (and Michael Steinmetz in Lee Hood's group) successfully implemented was considered very risky at the time, but it turned out to be surprisingly easy-''surprisingly'' because the high level of similarity among mammalian genes had not yet been appreciated. It is ironic that both in the human and in the murine systems, those groups that had obtained HLA or H-2 class I cDNA clones with great difficulty and strenuous efforts did not succeed in timely gene isolation. In both cases, they were ''scooped'' by comparative outsiders who had been allowed access to these precious cDNAs, although only for nonhomologous screening, which was erroneously expected to be very tricky. Exhaustion of the ''cDNA groups'' after their hard-won success may also have played a role.
As is obvious from this story, connections are essential in such a competitive game. Had Franc xois Kourilsky not been Philippe's brother, the Pasteur group would surely have hesitated to entrust such a valuable probe to a relatively obscure group 7 with no record in molecular immunology. And, later in the game, the environment at CIML clearly played a major role, first in having a ready-to-use functional expression system already in place (the LMTK-transformation assay in Pierre Golstein's group) and then in providing a number of monoclonal and polyclonal antibodies that, with Franc xois Lemonnier's group, allowed a large number of serological studies on HLA proteins coded by cloned genes and expressed on the surface of transformed cells. All this was also greatly helped by the collaborative climate fostered within CIML by its two founders and by the enthusiastic support of Franc xois Kourilsky. On the other hand, we largely missed the really functional studies looking at interactions with cytotoxic and helper T cells, essentially because these were not used in the human system within our institute.
5
With a publication whose title, on the proofs, read ''HLA cosmid clones show complete, wisely spaced human class I genes'' instead of ''widely''-a mistake caught just in time! 6 NCBI reference sequence NR_001434.1. HLA-H should not be confused with the HLA-like gene involved in hereditary hematochromatosis, initially called HLA-H and then renamed HFE, which lies $2 Mb telomeric to HLA-H (Figure 2 ).
7
In the years before my move to CIML, my small group had published a number of respectable articles in the Journal of Molecular Biology (highly regarded at the time), but the topic (the structure and processing of small ribosomal RNAs) was not considered to be fashionable and, to be honest, was indeed rather dull.
Finally, it is hard to deny the role of luck in a scientific success story. As I have emphasized in my narrative, the first sequencing run on the first fragment isolated from the first genomic clone brought back from Pasteur turned out to hit in the most conserved (and therefore most recognizable) part of the coding sequence. And the fact that this initial clone was found, after much sequencing, to contain a complete gene was also a stroke of luck. In a more general sense, my recently acquired skills (restriction mapping, labeling, and sequencing) were well adapted to the task at hand, and Pierre Golstein's decision to launch himself into the LMTKsystem months before (and for quite different purposes) was another lucky break. HLA gene cloning at CIML was the start of a long story with many participants, with successes and, of course, some setbacks as well. It definitely put my group, and CIML, on the map for molecular genetics applied to immunology and marked the beginning of the spread of molecular biology approaches to most groups within the Institute-a shift that was maybe overdue, but that still had not occurred in many immunology meccas all over the world. Many of the actors of this game (notably the Malissens) have now left their mark on immunogenetics and on the functional understanding of the immune system. It is somewhat uncanny to reflect, almost 30 years later, how it all started with a small stretch of DNA sequence read on a wet X-ray film on the morning of December 22, 1980.
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